Clinical trials: Sorafenib
Renal Cell Carcinoma
Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC)
The purpose of this study is to determine the safety and efficacy of combined stereotactic body radiotherapy (SBRT) + sorafenib in the treatment of patients with Stage IV renal cell carcinoma (RCC) who have recurred locally…
- Trial name
- NCT00672178
- Testing
- Stereotactic body radiation
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Refractory Hurthle Cell Thyroid Cancer
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
This randomized phase II trial studies the effects, good and bad, of using everolimus along with sorafenib tosylate versus sorafenib tosylate alone in treating patients with advanced radioactive iodine refractory thyroid cancer.
- Trial name
- NCT02143726
- Testing
- sorafenib, everolimus
- Where
- 21 sites in United States
- Volunteers
- 35 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatoblastoma
A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
Hepatoblastoma is the most common malignant liver tumor in infants and preschool children, comprising 65% of pediatric liver malignancies in those under 15, with its incidence on the rise in recent years [1].
- Trial name
- NCT07300449
- Testing
- Very low-risk group, Low-risk group, Intermediate-risk group
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Kidney Cancer
Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00492258
- Testing
- sorafenib tosylate, adjuvant therapy
- Where
- 39 sites in United Kingdom
- Volunteers
- 1,656 people
- Sponsor
- Medical Research Council
T Cell Lymphoma
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
This study will be a pilot study of sorafenib 400mg PO twice daily in refractory T-cell lymphomas including peripheral T-cell lymphoma (PTCL), angioimmunoblastic lymphadenopathy (AILD), cutaneous T cell lymphoma (CTCL)…
- Trial name
- NCT01561833
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University